JPD: What factors affect the long-term quality of life in the treatment of Parkinson's disease with levodopa-carbidopa intestinal gel?

Levodopa is the gold standard for the treatment of Parkinson's disease (PD), but it has a short plasma half-life and can cause motor fluctuations and dyskinesias

After 12 months, OFF time was significantly reduced (3.

Non-motor symptoms (Non-motor Symptom Inventory [NMSSI]), sleep measures (Parkinson's Disease Sleep Scale [PDSS-2] and NMSS sleep subdomain; both P ≤ 0.

However, activities of daily living (Unified Parkinson's Disease Rating Scale [UPDRS II]) and motor symptoms (UPDRS III) did not change significantly

At baseline, HRQoL was moderately positively correlated with activities of daily living (UPDRS II, PCC=0.

Improvements in HRQoL were not associated with improvements in OFF time or dyskinesia time

The significance of this study is that it found that HRQoL was associated with both baseline and baseline changes in dyskinesia, activities of daily living, and non-motor symptoms (including sleep), both at baseline and at 12 months ; but not with baseline or OFF Changes in time are irrelevant